A prognostic model for platinum-doublet as second-line chemotherapy in advanced non-small-cell lung cancer patients

Hongnan Mo, Xuezhi Hao, Yutao Liu, Lin Wang, Xingsheng Hu, Jianping Xu, Sheng Yang, Puyuan Xing, Youwu Shi, Bo Jia, Yan Wang, Junling Li, Hongyu Wang, Ziping Wang, Yan Sun, Yuankai Shi

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Poor prognosis of advanced non-small-cell lung cancer (NSCLC) patients and the promising therapeutic effect of platinum urge the oncologists to evaluate the role of platinum doublet as second-line chemotherapy and establish the definition of platinum sensitivity in NSCLC. We retrospectively analyzed 364 advanced NSCLC patients who received platinum-doublet regimens as second-line chemotherapy after platinum-based first-line treatment. Patients were divided into four groups by their time-to-progression (TTP) after first-line chemotherapy: 0–3, 4–6, 7–12, and >12-month group, respectively. Treatment efficacy of patients' overall survival (OS), progression-free survival (PFS), and response rate (RR), as well as treatment-related toxicity, were compared among the four groups. A prognosis score system and a nomogram were established by Cox proportional hazard model, and validated by concordance index (c-index). Median OS was 14.0, 16.0, 20.0, 25.0 months for patients in the 0–3, 4–6, 7–12, >12-month group, respectively. Age ≤60 years (P = 0.002), female (P = 0.019), and TTP>12 months (P = 0.003) were independent prognostic factors. Prognostic score was calculated by adding 1 point each for any of the above three indicators, with a c-index of 0.590 (95% confidential interval [CI], 0.552–0.627). Median OS were equal to 25.0, 16.0, and 11.0 months for best (2–3 points), intermediate (1 point) and worst (0 point) category, respectively (P < 0.0001). A nomogram that integrated patient's age, gender, and TTP for OS has a c-index of 0.623 (95% CI, 0.603–0.643). Female, younger than 60 years, and TTP greater than 12 months may indicate prolonged survival after platinum-doublet second-line chemotherapy in advanced NSCLCpatients.

Original languageEnglish
Pages (from-to)1116-1124
Number of pages9
JournalCancer Medicine
Issue number6
StatePublished - Jun 1 2016


  • Antineoplastic combined chemotherapy protocols
  • Carcinoma
  • Non-small-cell lung
  • nomograms
  • prognosis
  • treatment outcome


Dive into the research topics of 'A prognostic model for platinum-doublet as second-line chemotherapy in advanced non-small-cell lung cancer patients'. Together they form a unique fingerprint.

Cite this